

United States Patent [19]

Baylink

[11] Patent Number: 4,911,931

[45] Date of Patent: Mar. 27, 1990

[54] PHARMACEUTICAL COMBINATION FOR TREATMENT OF BONE-WASTING DISEASES

[76] Inventor: David J. Baylink, 1534 Fern Ave. W., Redlands, Calif. 92373

[21] Appl. No.: 80,759

[22] Filed: Aug. 3, 1987

[51] Int. Cl.⁴ A61K 33/42; A61K 33/14; A61K 31/415

[52] U.S. Cl. 424/606; 424/673; 424/676; 514/389

[58] Field of Search 424/131, 128, 151, 153; 514/822, 389, 391, 54, 12, 11; 260/397.2; 548/313, 312

[56] References Cited

U.S. PATENT DOCUMENTS

4,386,100	5/1983	Brittain et al.	514/389
4,501,754	2/1985	Wechter et al.	514/456
4,686,104	8/1987	Bockman et al.	424/131
4,726,952	2/1988	Walsdorf et al.	424/476

OTHER PUBLICATIONS

Melsen, F. et al., (1985), "A Quantitative Analysis of Bone Changes Following Anticonvulsant Therapy", Universal Institute of Pathology, pp. 247-251.

Harris, M. et al., (1978), "Anticonvulsant Osteomalacia Induced in the Rat by Diphenylhydantoin", Caleif. Tiss. Res. 25, 13-17.

Wolschendorf, K. et al., "A Quantitative Determination of Anticonvulsant-Induced Bone Demineralization by an Improved X-ray Densitometry Technique", Neuro-radiology 25:315-318, (1983).

Richens, A. et al., (1970), "Disturbance of Calcium Metabolism by Anticonvulsant Drugs", British Med. Jour. 4:73-76.

Johnell, O. et al., (1979), "Bone Morphology in Epileptics", Calcif. Tissue Int. 28:93-97.

Mosekilde, L. et al., (1976), "Anticonvulsant Osteomalacia Determined by Quantitative Analysis of Bone Changes", Acta med. scand. 199:349-355.

Israel, H., (1974), "Abnormalities of Bone and Orofacial Changes from Anticonvulsant Drugs", 34:104-105.

Lidgren, Lars et al., (1979), "Bone Mineral Content in Epileptics", Calcif. Tissue Int. 28:99-102.

Tjellesen, L. et al., (1985), "Different Actions of Vitamin D₂ and D₃ on Bone Metabolism in Patients Treated with Phenobarbitone/Phenytoin", Calc. Tiss. Int. 37:218-222.

Christiansen et al., (1973), "Incidence of Anticonvulsant Osteomalacia and Effect of Vitamin D: Controlled Therapeutic Trial", Brit. Med. J. 4:695-701.

Calkin et al., (1986), "Osteoporosis", The Practice of Geriatrics, pp. 466-476.

Krane, S., (1988), "Disorders of Bone Formation and Bone Resorption", Scientific American Section, Rheumatology, Chapter 11, p. 3.

Aurbach et al., (1981), Textbook of Endocrinology, 6th ed., Chapter 19.

Chem. Abstracts, 89(9):71112m, "Assessment of Calcium-Phosphate Metabolism Disturbances in Patients on Long-term Treatment w/Diphenylhydantoin", Pupek-Musialik, 1978.

Chem. Abstracts, 85(19):137564m, "Osteomalacia in Epileptic Patients treated with Anticonvulsants", Christiansen et al., 1974.

Chem. Abstracts, 73(11):54302a, "The Osteogenic Hypertrophic and the Teratogenic Effects of Sodium Diphenylhydantoin", Baratieri et al., 1969.

Journal of Med. Chem., 1981, 24(7), 843-7, Henderson et al.

Compendium of Drug Therapy, (1983/1984), Biomed. Information Inc., pp. 15:5-7.

Primary Examiner—Douglas W. Robinson

Assistant Examiner—Raymond J. Henley, III

Attorney, Agent, or Firm—Richard L. Neeley

[57]

ABSTRACT

A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

18 Claims, 1 Drawing Sheet